Correlation Between Changes in Lung Function and Changes in Cough and Dyspnoea in Nintedanib-treated Connective Tissue Disease Interstitial Lung Disease (CTD-ILD) Patients

Inclusion Criteria:

• Age ≥18 years with a confirmed physician diagnosis of connective tissue disease (CTD) associated Progressive Fibrosing Interstitial Lung Disease (PF-ILD)

• Have been prescribed nintedanib according to the local Summary of ProductCharacteristics (SmPC) and clinical judgment. Therapy with nintedanib must have beenstarted for clinical reasons independently from the intended patient enrolment intothe study at a maximum of 15 days before enrolment into the trial.

Exclusion Criteria:

• Patients currently receiving treatment with any investigationaldrug/device/intervention or who have received any investigational product within 1month or 5 half-lives of the investigational agent (whichever is longer) before thecommencement of therapy with nintedanib

• Patients at baseline with a known condition or reason that will result in withdrawalfrom the study before the 24-month time point

• Pregnancy or lactation